July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
One-year outcome of metamorphopsia and prognostic factor following intravitreal ranibizumab injection for branch retinal vein occlusion
Author Affiliations & Notes
  • Yoshimi Sugiura
    Department of Ophthalmology, University of Tsukuba, Tsukuba, IBARAKI, Japan
  • Fumiki Okamoto
    Department of Ophthalmology, University of Tsukuba, Tsukuba, IBARAKI, Japan
  • Tomoya Murakami
    Department of Ophthalmology, University of Tsukuba, Tsukuba, IBARAKI, Japan
  • Shohei Morikawa
    Department of Ophthalmology, University of Tsukuba, Tsukuba, IBARAKI, Japan
  • Takahiro Hiraoka
    Department of Ophthalmology, University of Tsukuba, Tsukuba, IBARAKI, Japan
  • Tetsuro Oshika
    Department of Ophthalmology, University of Tsukuba, Tsukuba, IBARAKI, Japan
  • Footnotes
    Commercial Relationships   Yoshimi Sugiura, Alconpharma (F), Bayer (F); Fumiki Okamoto, Alconpharma (F), Bayer (F), Nidek (F), Pfizer (F), Santen (F), Tsukuba University (P); Tomoya Murakami, None; Shohei Morikawa, None; Takahiro Hiraoka, Alconpharma (F), Carl Zeiss (F), Otsuka (F), Pfizer (F), Santen (F); Tetsuro Oshika, Alcon (F), Alcon (C), HOYA (F), HOYA (C), Johnson& JohnsonVision (F), Johnson & Johnson Vision (C), Kai (F), Kowa (F), Mitsubishi Tanabe (F), Novartis (F), Otsuka (F), Pfizer (F), Santen (F), Santen (C), Senju (F), Tomey (F), Topcon (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4050. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yoshimi Sugiura, Fumiki Okamoto, Tomoya Murakami, Shohei Morikawa, Takahiro Hiraoka, Tetsuro Oshika; One-year outcome of metamorphopsia and prognostic factor following intravitreal ranibizumab injection for branch retinal vein occlusion. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4050.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the effects of intravitreal ranibizumab injection (IVR) on metamorphopsia in patients with branch retinal vein occlusion (BRVO), and to assess the prognostic factor of metamorphopsia. This is retrospective, observational study.

Methods : Thirty-three eyes of 33 patients with macular edema caused by BRVO who were followed up for at least 12 months after initial treatment. There were 15 males and 18 females, averaging 67.2 ± 9.3 years of age (mean ± SD). All patients were treatment naïve. The severity of metamorphopsia was quantified using the M-CHARTS and retinal microstructure was assessed with optical coherence tomography (OCT) before and from 1 to 12 months after treatment. Based on OCT images, we assessed disorganization of the retinal inner layers (DRIL) at the first month after resolution of the macular edema (early DRIL) and at 12 months after treatment (after DRIL). We also evaluated central retinal thickness (CRT), presence of serous retinal detachment, and status of the external limiting membrane (ELM) and ellipsoid zone (EZ).

Results : IVR treatment significantly improved best-corrected visual acuity (BCVA) and CRT (P < 0.0001, P < 0.0001, respectively), but the mean metamorphopsia score did not improve by treatment even after 12 months. Post-treatment metamorphopsia scores showed a significant correlation with pre-treatment metamorphopsia scores (P < 0.005), the extent of early DRIL (P < 0.05) and after DRIL (P < 0.05), and the number of injections (P < 0.05). Multivariate analysis revealed that the absolute value of the post-treatment mean metamorphopsia score was significantly correlated with the pre-treatment mean metamorphopsia score (P < 0.05).

Conclusions : In patients with BRVO, IVR treatment significantly improved BCVA and CRT, but not metamorphopsia. The severity of post-treatment metamorphopsia was significantly associated with the degree of pre-treatment metamorphopsia, the extent of DRIL and the number of injections. Prognostic factor of metamorphopsia was the degree of pre-treatment metamorphopsia.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×